The optical genome mapping space has garnered considerable interest among investors in recent times and one of the companies to have come into sharp focus for that reason is BioNano Genomics Inc (NASDAQ:BNGO).
The stock had rallied by 400% up until February since the start of the year. However, it tanked by 50% since, and hence, it is necessary to figure out if it is a stock worth buying in April. In order to understand the company, it should be noted that Bionano is best known for its product Saphyr.
It is an analysis system and helps in testing for genetic diseases. While the company is looking to boost the number of studies that look into the capabilities of Saphyr, it is also looking to build the next generation of the product. The size of the optical genome mapping market has not yet been determined by independent sources but at this point, it is a stock that might be more suited to aggressive investors.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.